jueves, 3 de mayo de 2018
FDA approves tisagenlecleucel for adults with relapsed or refractory large B-cell lymphoma May 1, 2018
FDA approved tisagenlecleucel (KYMRIAH, Novartis Pharmaceuticals Corp.) a CD19-directed genetically modified autologous T-cell immunotherapy, for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, high grade B-cell lymphoma and DLBCL arising from follicular lymphoma. More Information. May 1, 2018.
Suscribirse a:
Enviar comentarios (Atom)
No hay comentarios:
Publicar un comentario